The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.

@article{Tanaka2011TheSC,
  title={The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.},
  author={Hiroshi Tanaka and Miyuki Yoshida and Hiromi Tanimura and Toshihiko Fujii and Kiyoaki Sakata and Yukako Tachibana and Jun Ohwada and Hirosato Ebiike and Shino Kuramoto and Keiichi Morita and Yasushi Yoshimura and Toshikazu Yamazaki and Nobuya Ishii and Osamu Kondoh and Yuko Aoki},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2011},
  volume={17 10},
  pages={
          3272-81
        }
}
PURPOSE The phosphatidylinositol 3-kinase (PI3K) pathway plays a central role in cell proliferation and survival in human cancer. PIK3CA mutations, which are found in many cancer patients, activate the PI3K pathway, resulting in cancer development and progression. We previously identified CH5132799 as a novel PI3K inhibitor. Thus, this study aimed to clarify the biochemical and antitumor activity of CH5132799 and elucidate the correlation between CH5132799 response and genetic alterations in… CONTINUE READING
Highly Cited
This paper has 52 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 50 citations

53 Citations

0102030'13'15'17'19
Citations per Year
Semantic Scholar estimates that this publication has 53 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 48 references